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cult to achieve using current therapies [2]. Safer and
more effective avenues for treatment are urgently
needed. Liver glycogen phosphorylase controls the re-
lease of glucose-1-phosphate from liver glycogen stores
and plays a central role in hepatic glucose output. In
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inappropriately regulated and remains high when pro-1Exploratory Medicinal Sciences
2 Department of Cardiovascular duction is normally shut off (such as after a meal, when
digestion raises blood glucose levels), suggesting thatand Metabolic Diseases Biology
3 Medicinal Chemistry inhibitors of human liver glycogen phosphorylase may
be useful in treating diabetes. Studies have shown thatGroton Laboratories
Pfizer Global Research and Development serum glucose levels can be lowered significantly by
the inhibition of HLGP in a mouse model of diabetes [3, 4].Groton, Connecticut 06340
4 Center for Biomolecular Interaction Analysis Typically, drug-development efforts have focused on
compounds that bind at the catalytic sites of enzymes,University of Utah
School of Medicine but here we consider the possibility of allosteric inhibi-
tors, several of which have been recently described [5].Salt Lake City, Utah 81432
HLGP is a highly regulated allosteric enzyme that
switches between activated and inactivated forms de-
pending on the phosphorylation state of the enzymeSummary
and the presence of allosteric activators and inhibitors
that bind to multiple, distinct loci. In theory, each ofHuman liver glycogen phosphorylase (HLGP) cata-
the allosteric sites on HLGP could be a potential druglyzes the breakdown of glycogen to maintain serum
binding site. Known allosteric inhibitors of this enzymeglucose levels and is a therapeutic target for diabetes.
include Bayer W1807, which localizes to the nucleotideHLGP is regulated by multiple interacting allosteric
binding site [6, 7], and sugar derivatives that are found atsites, each of which is a potential drug binding site.
the glucose inhibitor site [8]. In addition, a novel (perhapsWe used surface plasmon resonance (SPR) to screen
nonphysiological) binding site, termed the indole inhibi-for compounds that bind to the purine allosteric inhibi-
tor site, was identified crystallographically in HLGP us-tor site. We determined the affinities of a series of
ing a series of compounds synthesized at Pfizer [9, 10].compounds and solved the crystal structures of three
To develop screening methods specific for ligandsrepresentative ligands with KD values from 17–550M.
which bind at the allosteric effector sites, we used theThe crystal structures reveal that the affinities are
purine inhibitor site of HLGP, which is known to actpartly determined by ligand-specific water-mediated
synergistically with glucose. This synergism is a resulthydrogen bonds and side chain movements. These
of the proximity of the purine and glucose binding siteseffects could not be predicted; both crystallographic
to each other and to the catalytic site. Both glucose andand SPR studies were required to understand the im-
purines inhibit HLGP by stabilizing the inactive confor-portant features of binding and together provide a ba-
mation of the enzyme, in which substrates are preventedsis for the design of new allosteric inhibitors targeting
from entering the catalytic site. Glucose dependencythis site.
could be a useful property in an HLGP inhibitor intended
for diabetic patients. A drug that provides reduced inhi-Introduction
bition when glucose levels are low and increased inhibi-
tion in the presence of elevated glucose levels couldIn the United States, 8 million people have been diag-
reduce the risk of dangerous hypoglycemic episodesnosed (a similar number are estimated to be affected but
while still retaining efficacy when needed.undiagnosed) with type 2 diabetes mellitus, a disease
Using surface plasmon resonance technology, wecharacterized by high serum glucose levels and compli-
measured binding affinities of commercially availablecations that include nerve and kidney damage, blind-
compounds expected to bind at the purine site. Theseness, premature atherosclerosis, and heart disease [1].
compounds are expected to function kinetically as allo-The metabolic basis of the disease is not well under-
steric inhibitors. The SPR assay was reliable and ex-stood but consists of both resistance to insulin action
tremely sensitive, enabling the detection of small mole-and defects in pancreatic insulin secretion. Exacting
cules to a protein 500-fold greater in mass. In addition,control of plasma glucose levels significantly reduces
binding of small molecules to inactive states of the en-the extent and progression of complications but is diffi-
zyme were measured, information which may be impor-
tant for understanding the longevity and distribution of
5 Correspondence: virginia@thiospharm.com the drug in vivo.6 Current address: Thios Pharmaceuticals, Inc., 747 Fifty Second
Subsequent to the SPR studies, we determined theStreet, Oakland, California 94609.
crystal structures of HLGP complexed with three differ-7 Current address: Department of Biochemistry and Biophysics, Uni-
versity of California, San Francisco, California 94143. ent purine site compounds (one flavin and two purines;
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Table 1. Crystal, Data Collection, and Refinement Statistics for the HLGPa and HLGPb Complexes Described
HLGPa/caffeinea, HLGPa/uric acid, HLGPa/riboflavin, HLGPb/caffeinea,
CP-403700, CP-403700, CP-403700, CP-403700,
GlcNAc GlcNAc GlcNAc GlcNAc
Data Collection/Scaling
Space group P3(1) P3(1) P3(1) P3(1)
Cell dimensions a  124.7 A˚ a  124.0 A˚ a  124.4 A˚ a  124.1 A˚
b  124.7 A˚ b  124.0 A˚ b  124.4 A˚ b  124.1 A˚
c  124.5 A˚ c  123.3 A˚ c  124.0 A˚ c  123.8 A˚
Resolution 99–2.1 A˚ 99–2.1 A˚ 99–2.1 A˚ 35–2.3 A˚
Reflections 183,471 243,830 368,381 261,069
Unique 113,786 117,831 122,788 92,608
Redundancy 1.6 2.0 2.9 2.8
Completeness (%) 90.0 (60.3) 94.9 (75.5) 98.1 (95.3) 99.2 (97.3)
Rsym (%) 6.6 (47.5) 7.0 (41.7) 9.2 (41.8) 8.9 (41.3)
I/ 9.4 (1.4) 9.6 (1.7) 11.4 (2.6) 11.8 (2.7)
Structural Refinement
Resolution 50–2.25 A˚ 75–2.1 A˚ 99–2.1 A˚ 35–2.3 A˚
Rfactor 0.214 0.191 0.247 0.206
Rfree 0.243 0.235 0.283 0.253
Number of non-H atoms
Protein 12,837 12,858 12,840 12,882
Ligand 176 184 190 186
Water 602 779 539 466
B-factors (A˚2)
Protein 30.6 31.9 35.8 36.7
All ligands 26.5 27.2 34.5 32.8
Purine-site ligand 33.0 53.2 62.6b 37.7
Waters 28.0 33.5 32.3 35.3
Rms deviations
Bonds (A˚) 0.006 0.010 0.009 0.007
Angles () 1.2 1.5 1.4 1.3
Dihedrals () 21.1 21.8 21.3 20.9
Numbers in parentheses give the statistics for the highest resolution bin.
a The two caffeine-bound structures include four caffeine molecules, two at the purine site and two additional caffeine molecules bound on
the protein surface near Trp174. It is unlikely that this secondary site is biologically relevant, as it is removed from the dimer interface and
positioned on the surface of the protein, rather than in a pocket. The structures with uric acid and riboflavin show no compound electron
density at this second binding location.
b Riboflavin is considerably less well ordered in the second subunit. (B value for subunit 1, 50.4; B value for subunit 2, 75.4.)
Table 1) whose affinities ranged from 17 M to 550 M. bilization chemistry. To demonstrate that all effector
sites were accessible and that the protein could undergoThe differences in affinities are not explained by the
chemical structures of the inhibitors but can be rational- the conformational changes required for activity in the
chip environment, we assayed the ability of HLGP toized in light of the crystallographic data. Optimal binding
of the flavin compound is achieved by maximizing the bind known ligands. Here, we present data for two inhibi-
tor binding sites, the purine site and the glucose bindinghydrophobic contact to the protein. The smaller purine
compounds compensate for their reduced hydrophobic site.
The SPR method was first validated by measuring thesurface area through the formation of stabilizing hydro-
gen bonds with ordered water molecules. The crystal interaction between HLGPa and a purine site ligand,
caffeine. The raw biosensor data (Figure 1A) are dis-structures show that although all three ligands stack
between the phenylalanine and tyrosine side chains that played as a series of plots, termed sensorgrams, of
response units (RUs) measured over time for differentcomprise the site, each adopts a unique orientation
within that constraint. Each specific orientation is stabi- concentrations of caffeine. The number of RUs (y axis)
is a measure of the change in refractive index at thelized by hydrogen bonds to water molecules whose loca-
tions are specified by the ligand. Because of these and chip surface on ligand binding and is proportional to
other changes to the binding site, a crystallographic the mass of the ligand bound to the protein. The assays
analysis was essential to identify the key interactions. were done in triplicate; the superposition of the sen-
sorgram plots (Figure 1A) shows the sensitivity of the
method and that the data are reproducible even for lowResults and Discussion
RU values. The plot shows a sharp upward increase in
RUs on first injection of the ligand, indicating that theValidation of Biosensor Method
binding reaction rapidly reaches equilibrium. Similarly,Purified HLGPa (phosphorylated at serine 14) or b (un-
when the ligand is no longer present in the sample flow-phosphorylated) was coupled to a CM5 BIACORE bio-
sensor chip via free amine groups using standard immo- ing over the chip, the RU values drop precipitously,
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Figure 1. SPR Analysis of the Caffeine/
HLGPa Interactions
(A) Binding responses were measured for caf-
feine (500 M–2 M by 2-fold dilutions) in-
jected over a surface to which 21,000 RU
HLGPa had been coupled.
(B) Equilibrium analysis of the caffeine/
HLGPa interaction. Equilibrium binding re-
sponses for caffeine in the absence (filled
squares) and presence (filled circles) of 50
mM glucose were independently fit to a 1:1
interaction model (solid lines) to determine
equilibrium dissociation constants.
signaling that dissociation is also very fast. The raw model describing the nature of the interaction. In this
case, a single affinity model, shown by the curve drawnsensorgram suggests that the interaction is relatively
weak. through the individual data points, provides an excellent
fit to the data. Based on the quality of the fit and itsTo extract out equilibrium binding constants, the sen-
sorgram data can be combined and replotted as RU reproducibility (chips coupled with 10–20,000 RU; our
unpublished data), more complicated models, such asvalues at equilibrium versus ligand concentration (Fig-
ures 1B and 2). The data points may then be fitted to a mass transport limited, were not considered [11]. We
Figure 2. Purine Site Screen
For each of the 18 compounds tested, the
RU values at equilibrium versus ligand con-
centration were fitted to a 1:1 interaction
model. The resulting fitted curves are super-
imposed and listed in order on the right start-
ing from the curve closest to the upper left
(riboflavin) to the curve closest to the lower
right (allantoin), with the labels color coded
to match their respective binding isotherms.
For clarity, only the curves for riboflavin, caf-
feine, and uric acid are labeled directly.
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Table 2. Properties and SPR-Determined KDs of Purine Site Ligands
Percentage of HLGPa HLGPb
Solvent-Accessible Ligand Buried in No. of No. of Hydrogen- KD KD
Surface Area (A˚2) Crystal Structure Mass (Da) Rotatable Bonds Bonding Groups (M)a (M)a
Riboflavin 581 55% 376.37 11 9 17 15
Lumiflavine 431 256.26 3 5 20 18
FMN 677 456.30 14 12 70 50
FAD 1,054 785.56 24 23 80 70
Xanthopterin 305 179.14 1 7 85 69
Caffeine 382 65% 194.19 3 3 108 92
Theophylline 346 180.17 2 4 150 120
1-methylxanthine 301 166.10 1 5 250 210
7-methylxanthine 314 166.10 1 5 280 260
Xanthine 293 152.11 0 6 320 290
Folic acid 689 441.40 11 13 380 470
3-methylxanthine 301 166.10 1 5 390 330
Allopurinol 260 136.11 1 5 420 370
Uric acid 399 53% 168.11 0 7 550 510
Hypoxanthine 273 136.11 0 5 1,220 1,130
Adenosine 451 267.24 6 9 1,370 1,310
Inosine 429 268.23 6 9 1,670 1,530
6-biopterin 421 237.22 6 8 1,770 1,750
Allantoin 278 158.12 3 7 7,960 9,560
a Each measurement is the average of duplicate experiments. The errors from duplicate measurements averaged 15% for the entire dataset.
assume that the biologically relevant symmetrical dimer Screen of the Purine Inhibitor Site
We used the biosensor to evaluate the affinities of abinds two molecules of caffeine, as there is no evidence
series of ligands expected to bind at the purine site,for half-site reactivity for any of the ligands that bind to
which had been previously assayed kinetically [14]. AHLGP. The midpoint of the curve gives the value for the
similar protocol could be used to target any one of theaffinity constant, KD, of HLGPa for caffeine (108 / 10
allosteric loci. The biosensor chip contains four separateM). The error was determined experimentally by the
channels, permitting the screening of up to three differ-average of five separate experiments. These results
ent protein samples side by side, with the fourth channelshow that the biosensor assay is sufficiently sensitive to
serving as a reference. In this experiment, we used twodistinguish binding of a small molecule to a partner 500-
channels for reference measurements and attached afold greater in mass (194 Da compared to 100,000 Da).
sample of the phosphorylated and unphosphorylatedPrevious studies of glycogen phosphorylase from rab-
forms of human liver glycogen phosphorylase to thebit muscle [12] and rat liver [13] have shown that inhibi-
other two channels. We tested 18 commercially avail-tion by glucose and caffeine is synergistic. To confirm
able compounds (Table 2) and identified compoundsthat the HLGPa was in a biologically relevant state on
that bound with both higher and lower affinities thanthe biosensor chip, we measured the effect of glucose
caffeine. Riboflavin bound to HLGPa with the higheston the enzyme’s affinity for caffeine. We were able to
affinity (KD  17 M), and allantoin bound with the weak-observe glucose synergism by measuring the signal for
est affinity (KD  7.9 mM), spanning a 470-fold differencecaffeine in the presence and absence of 50 mM glucose
in binding constants.(Figure 1B). Analysis of the biosensor data revealed the
Under these conditions, the affinities of the 18 com-expected 2-fold difference in the KDs for caffeine: 108 pounds for the HLGPa and HLGPb forms of the enzyme
M without glucose and 65 M with 50 mM glucose.
are of the same order of magnitude (Table 2). In theory,
The observed synergistic effects of caffeine and glucose
an allosteric inhibitor should have a higher affinity for
indicate that HLGP functions as expected on the dextran the inactive form of the enzyme (HLGPb ) than the active
chip surface. form (HLGPa ). Such a change in ligand affinity is inter-
We compared the affinities determined from the bio- preted as a displacement of the inactive to active confor-
sensor assay with data reported in the literature. The Ki mation equilibrium of the enzyme [15]. These affinities
for caffeine binding to rabbit muscle glycogen phos- are usually measured by kinetic assays; for example,
phorylase a (RMGPa ) is 100 M [12]; the KD for caffeine AMP has a higher affinity for the active conformation
binding to HLGPa measured on the biosensor is 108 (KD 2M; [16, 17]) than the inactive conformation (KD
M. Thus, the results obtained using a strict binding 200M; [18]). We do not observe an affinity difference of
assay on the biosensor are in the same range as those this scale in the SPR assay, most likely because for
obtained from a kinetic analysis. The correspondence HLGP the effect is not visible in the absence of sub-
between binding and enzymatic data strongly suggests strates. We observe the same result testing other ligands
that the affinities measured using the biosensor repre- one at a time in the SPR assay; the affinities for AMP,
sent a biologically relevant state of the enzyme in solu- glucose, or glucose analogs for HLGPa and HLGPb are
tion. This correspondence occurs despite important ex- within the same order of magnitude, demonstrating that
perimental differences (temperature, buffer, presence the effect is not specific to the purine site (our unpub-
of activating substrates, and enzyme source) between lished data). We note that the strength of the SPR assay
described here is that it allows us to measure binding ofour results and those reported in the literature.
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low affinity, low molecular mass compounds to specific it to the side chains of residues Asn282 and Glu287 and
sites on a 200 kDa enzyme. Rigorous confirmation that to the protein backbone at residues 283, 610, 612, and
the ligands binding to the purine site function kinetically 570. A direct hydrogen bond between the purine ring of
as allosteric inhibitors of HLGP requires a further analy- uric acid and the side chain oxygen of Asn282 is also
sis showing synergy with other ligands which stabilize formed. The hydrophobic and hydrogen bonding inter-
the inactive conformation (e.g., glucose) and that bind- actions observed involve residues belonging to both the
ing of the inhibitor accelerates dephosphorylation of the N- and C-terminal domains and likely serve to stabilize
enzyme (as has been done for the indole inhibitor site their relative orientations.
[9]). It is possible to develop an SPR screen that includes Uric acid has four potential hydrogen bonds that are
substrates; however, analysis of these results may be unsatisfied, three of which are located on the five-
more complicated. membered ring of the purine moiety and are buried
within the site. The absence of such interactions indi-
cates that uric acid is not an optimal ligand for this site.Compound Analysis
The average crystallographic B value (which may beWe calculated the hydrogen bonding potential, number
taken as a measure of the order of the ligand) of uricof rotatable bonds, mass, and solvent-accessible sur-
acid is 53.2. This value is about 2-fold higher than theface area for each compound and looked for correlations
average B value for caffeine, another ligand that bindsbetween these properties and the binding affinities.
to this site (Table 2), suggesting that uric acid is lessWithin the range of binding affinities observed, no corre-
well ordered by comparison, consistent with its weakerlations could be established.
affinity.
HLGPa binds caffeine with 5-fold greater affinity thanStructures of HLGPa/Purine Site Ligand Complexes
uric acid. Whereas uric acid interacts primarily with theTo understand the structural details responsible for the
aliphatic moiety of Tyr613, caffeine forms additional vanmeasured differences in affinities at the purine site, we
der Waals contacts with both the aliphatic and phenyldetermined the X-ray crystal structures of three ligand
groups of Tyr613. This is possible because the hy-complexes that span a 30-fold range in affinity: uric acid,
drophobic surface of caffeine is increased relative tocaffeine, and riboflavin. Each purine site ligand was co-
uric acid by its three methyl groups (Table 2). Althoughcrystallized with HLGPa and two additional inhibitors that
no direct hydrogen bonds are made between caffeineaided crystallization, presumably by stabilizing the protein
and the protein, water-mediated interactions specify itsconformation (N-acetyl--D-glucopyranosylamine, which
orientation. Caffeine forms hydrogen bonds to two or-binds at the glucose inhibitor site [19], and (S)-1-{2-[(5-
dered water molecules that link it to the main chain ofchloro-1H-indole-2-carbonyl)-amino]-3-phenyl-propionyl}-
residues 283, 570, 573, and 610 and to the side chainsazetidine-3-carboxylate (CP-403,700), which binds at
of Glu382, Glu572, and Arg770 (Table 3 and Figure 3B).the indole inhibitor site [9]). In addition to the structures
Compared to uric acid, the purine ring of caffeine adoptssolved, allantoin, the weakest purine site ligand, was
a different rotational position in the binding site, therebyalso tested in numerous cocrystallization and soaking
optimizing the hydrogen-bonding network and avoidingexperiments. Although excellent crystals were obtained,
steric overlaps of the 1, 3, and 7 methyl substituents.no density corresponding to the ligand could be identi-
The hydrogen bonds formed to uric acid are not presentfied in any of the electron density maps.
in the caffeine complex due to the presence of the 1-methyl
group of caffeine. Instead, hydrogen bonds are formedDescription of the Purine Inhibitor Binding Site
to caffeine’s two carbonyl groups. In contrast to uricEach HLGP monomer is composed of two nearly equal
acid, there is only a single unsatisfied hydrogen-bondingsized domains; the catalytic site lies between the two.
partner in caffeine (N9), which is solvent accessible.Riboflavin, caffeine, and uric acid all bind at the purine
Early low-resolution studies of rabbit muscle phos-inhibitor site, which lies at the domain interface, approxi-
phorylase a (RMGPa ) crystals soaked with purine sitemately 12 A˚ from the catalytic site on the enzyme sur-
ligands revealed the location of the purine inhibitor siteface. The purine site can be minimally described as a
[20]. More recently, two high-resolution structures ofslot formed between two parallel aromatic side chains.
RMGP complexed with caffeine and other inhibitorsThe principal features are hydrophobic and electronic
have been determined (Protein Data Bank ID codesstacking interactions between the planar ligand and the
1C8L and 1GFZ [7]). Interestingly, the orientation of thearomatic side chains of Phe285 and Tyr613. In addition
caffeine purine ring in human liver glycogen phosphory-to the hydrophobic interactions, each compound forms
lase is distinct from that reported for RMGP. A compari-a specific set of water-mediated hydrogen bonds to
son of our HLGPa/caffeine structure and the two caf-residues surrounding the purine binding site.
feine-bound RMGP structures shows very good overlapOf the three complexes, the compound with the lowest
between the corresponding residues of the purine siteaffinity for HLGPa is uric acid (KD  550 M). Uric acid
and conservation of each of the waters we observe inter-(Figure 3A and Table 2) forms a strong ring-stacking
acting with caffeine; yet the caffeine molecule in RMGPinteraction with the aromatic group of Phe285. Its posi-
is flipped 180 degrees relative to the caffeine in ourtion relative to the ring of Tyr613 is slightly offset so that
structure. The two different rotational positions offer thethe primary interaction is with the C and C atoms of
same number of hydrogen-bonding groups in similarTyr613, rather than with the phenyl ring. Uric acid is
locales. The electron density for our HLGPa complexoriented in the binding site through hydrogen bonds
with three ordered water molecules (Table 3) which link clearly supports our chosen orientation (Figure 3B).
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Figure 3. Crystal Structure of HLGPa/Purine
Site Ligands
(A), Uric acid bound at the purine site; (B),
caffeine bound at the purine site; (C), ribofla-
vin bound at the purine site. The 2Fo-Fc differ-
ence electron density for each ligand is con-
toured at 1 above the mean. The figures
were prepared using Ribbons [31], and each
panel is colored as follows: structural ele-
ments of the N-terminal domain, red; those of
the C-terminal domain, blue; oxygen atoms,
red; nitrogen atoms, blue; carbon atoms,
green; and water molecules are shown as red
spheres.
Effect of Phosphorylation on Binding The purine site is preformed in the inactive conformation
of human liver glycogen phosphorylase. The inactive con-and Conformation
A comparison of the crystal structures of the phosphory- formation of HLGPa complexed with CP-403,700, a
glucose analog, and caffeine may be compared with thelated and unphosphorylated enzymes complexed with
caffeine, N-acetyl--D-glucopyranosylamine, and CP- structure of HLGPa complexed with the glucose analog
alone (purine site empty). A comparison of the caffeine-403,700 confirms that the inactive conformation of the
enzyme described here is independent of the phosphor- bound and uric acid-bound structures with this inactive
HLGPa [21] reveals that the positions of the phenylylation state of the protein. The crystal structures of
caffeine-bound HLGPa and caffeine-bound HLGPb look groups of Phe285 and Tyr613 overlap well in all three
structures. Thus, the binding of caffeine or uric acididentical within error; the unphosphorylated N terminus
is disordered in the HLGPb structure (as seen in the does not create the binding site but serves to further
stabilize an inactive conformation in which it alreadyphosphorylated HLGPa structure), and no structural
changes are transmitted to the purine or glucose inhibi- exists.
In contrast, the structure of HLGPa activated by AMPtory sites.
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Table 3. Key Interactions between Purine Site Ligands and HLGP
Group 1 Group 2 Distance
HLGPa-uric acid Uric O6 W 2001 2.4 A˚
Uric N1 Asn282 O	1 2.9 A˚
Uric O2 W 2003 3.0 A˚
Uric O2 W 2002 2.9 A˚
aUric O6 Phe285 C 3.2 A˚




Uric N7 Tyr613 C	2 3.4 A˚
Uric O8 Tyr613 C 3.4 A˚
Uric C5 Tyr613 C 3.6 A˚
HLGPa-caffeine Caffeine O6 W 2001 2.6 A˚
Caffeine O2 W 2004 2.6 A˚
aCaffeine O6 Phe285 C 3.3 A˚
Caffeine C6 Phe285 C 3.4 A˚
Caffeine N1 Phe285 C	1 3.5 A˚
Caffeine C6 Tyr613 C 3.4 A˚
Caffeine C2 Tyr613 C
1 3.4 A˚
Caffeine C1 Tyr613 C
2 3.6 A˚
HLGPa-riboflavin Riboflavin O4 W 2001 2.6 A˚
Riboflavin N3 W 2002 2.9 A˚
aRiboflavin O4 Phe285 C 3.2 A˚
Riboflavin C4 Phe285 C 3.3 A˚
Riboflavin C4A Phe285 C	1 3.3 A˚
Riboflavin C2 Tyr613 C 3.5 A˚
Riboflavin C5A Tyr613 C
2 3.5 A˚
Riboflavin C1 Tyr613 OH 3.5 A˚
Riboflavin C8 Glu382 C 3.4 A˚
Riboflavin C8M Glu382 C	 3.4 A˚
Riboflavin C7M Tyr573 C	2 3.5 A˚
a The three shortest atom to atom van der Waals contacts are given to facilitate comparison of the stacking interactions between each
compound and the nearby Phe and Tyr rings.
[21] does not present a purine site capable of binding groups. Because both uric acid and caffeine lack the
hydrophobic surface area required to pack againstcaffeine. The two C-terminal domains of the caffeine-
bound inactive enzyme and the AMP-bound active confor- Glu382, no side chain rotation is seen, and only one
terminal oxygen of Glu382 interacts with Arg770.mation overlap well, placing Tyr613 in identical positions.
However, in the active conformation, the loop containing As in the complex with caffeine, no direct hydrogen
bonds are formed between the protein and the riboflavinPhe285 (the 280’s loop) is displaced. Phe285 is moved
14 A˚ from its position in the caffeine-bound structure, ligand. Water-mediated hydrogen bonds are formed be-
tween the flavin and backbone atoms of residues 283,displacing one wall of the slot observed in the inactive
form. In agreement with this result, caffeine could not 570, 610, and 612, as well as with the side chain of
Asn282 (Table 3). The ribose moiety is partially disor-be soaked into or cocrystallized with the enzyme under
the AMP complex crystallization conditions. dered, but weak interactions (distances of 3.2 to 4.0 A˚)
can be observed between the ribose hydroxyls, two
bound waters, and the side chains of Glu572 and Arg770.Binding of Flavins at the Caffeine Site
The highest affinity compound identified from our screen Riboflavin has one unsatisfied hydrogen bond at its N5
position, which is not accessible to solvent.was riboflavin (KD  17 M; Table 2 and Figure 3C). The
increased hydrophobic surface area of riboflavin relative The three crystal structures provide a basis for under-
standing the affinity constants for the purine analogs.to the two-ring systems of uric acid and caffeine allows
more extensive contacts with the aliphatic and ring moi- Uric acid, the weakest binder, buries the least solvent-
accessible surface area in the complex and exhibitseties of both Phe285 and Tyr613, contributing to im-
proved binding. Several adjustments of the binding site high B values, suggesting some disorder in the bound
conformation. Uric acid also suffers from unsatisfiedare required to accommodate the larger ring system of
riboflavin. Side chain movements result in an altered hydrogen bonds at three positions oriented deep into
the binding site as well as one oriented toward the bulkbinding site, in which the hydrophobic interactions be-
tween riboflavin and the protein are optimized. In partic- solvent. These unsatisfied hydrogen bonds may contrib-
ute to disorder and detract from the binding affinity. Theular, the phenyl group of Phe285 is rotated around the
chi1 dihedral approximately 1 A˚ toward the center of 5-fold improved binding of caffeine relative to uric acid
is consistent with the lower B values of caffeine andthe flavin ring system, resulting in an improved stacking
interaction. The chi3 dihedral angle of Glu382 is also may be explained by improved hydrophobic interactions
and a fully satisfied network of hydrogen bonds linkingaltered to maximize packing of its side chain against the
flavin ring. The salt bridge between Glu382 and Arg770 caffeine to the protein through water molecules. The 30-
fold improved binding of riboflavin relative to uric acid(Figure 3C) is optimized, such that both of its terminal
oxygens are linked to one of the arginine terminal amino can be attributed to the burying of a larger hydrophobic
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surface area and to side chain movements that serve phorylase. The flavin compounds exhibit the highest
to optimize the interactions between the ligand and its affinity, followed by purines, of which caffeine binds with
binding site. the highest affinity. This set of binding and crystallo-
One potential high-affinity compound that we did not graphic data provides a basis from which allosteric ef-
test is flavopiridol, a flavanoid that acts as an ATP- fectors for the purine site could be developed.
competitive inhibitor of cyclin-dependent kinases. Using The crystal structure shows that the flavin moiety de-
kinetic rather than SPR assays, flavopiridol was shown rives its potency by interacting with only a fraction of
to inhibit RMGPa and RMGPb with IC50s of 2.5 M and the nearby hydrophobic surface. Side chain atoms of
1M, respectively. The structure of RMGPb with flavopi- Glu382 and Tyr573 (and potentially others) are within
ridol bound at the purine site has been determined [22]. van der Waals contact of the flavin C7 and C8 carbon
Flavopiridol consists of three moieties: a central flavone positions; such interactions could be optimized. The
2-ring system, a piperidine, and a pendant 2-chlorophe- fully conserved structural water (W2001) could be incor-
nyl group. Like riboflavin, the interactions of flavopiridol porated into the ligand through an extension off the
at the purine site are primarily hydrophobic (600 A˚2 of flavin carbon C4. Although the flavin nitrogen N5 likely
solvent accessible area buried, compare to 581 A˚2 for participates in a hydrogen bond in solution, it does not
riboflavin). Flexibility in flavopiridol allows for optimized in the complex; this feature could be exploited. Finally,
placement of the chlorine substituted phenyl group, charged residues Glu382, Glu572, and Arg770 are within
which occupies roughly the same space as the hy- hydrogen-bonding range of the ribose moiety; their
drophobic end of the flavin ring in our HLGPa/riboflavin proximity could be utilized. From these observations,
structure. The flavone ring does not overlap well with we conclude that riboflavin, because it exploits only
the flavin moiety of riboflavin, being 15 out of the plane some of the potential interactions at this site, is not an
and rotated 45 with respect to riboflavin. The piperidine optimal inhibitor. We also considered the possibility of
ring fills a similar space as the riboflavin ribosyl group linking the glucose and purine sites (which are only 10 A˚
and is structurally more rigid but forms no contacts apart) with a single compound; however, since the pro-
(neither direct nor water mediated) to surrounding resi- tein backbone (residues 283–285) occupies the region
dues of the protein. Flavopiridol forms hydrogen bonds that lies between these two sites, it would prevent bind-
to two ordered water molecules that correspond loosely
ing of any compound linking them. The crystallographic
to waters 2001 and 2002 observed in our riboflavin
data shown here provide a basis for the design of more
structure.
effective ligands for the purine site.
Flavopiridol and riboflavin are structurally distinct;Role of Water Molecules
however, the opportunities to improve the binding affin-Crystallographically observed waters in the binding site
ity of riboflavin may be equally applied to flavopiridol,likely play a critical role in determining the affinity of
with two exceptions. Flavopiridol already lacks theeach ligand for HLGP. Only one of these buried waters
floppy ribose, having a piperidine instead, and also lacks(W2001) is conserved in all three structures. Caffeine,
the unsatisfied ring nitrogen of flavin. Taken together,uric acid, and riboflavin all form hydrogen bonds with
these may account for its improved affinity to RMGPthis buried water, yet each compound presents a differ-
compared to riboflavin.ent functional group for this interaction and positions
We have demonstrated that SPR technology is usefulitself in a distinct conformation within the binding site.
as a complement to crystallographic analyses of ligandThis is of particular importance for the purine com-
binding. The SPR assay was sensitive enough to distin-pounds, which, due to their smaller volume, assume
guish binding of small molecules to a partner 500-folddifferent binding orientations depending on the nature
greater in mass and could likely be extended to a massof the attached functional groups.
ratio of 1000. The SPR assays measure direct binding,Additional water molecules are recruited to satisfy
are not dependent on enzyme activity, and could bepotential hydrogen bonds. Their absence or presence
used in a medium throughput mode; up to 200 com-is determined by steric conflicts and the ability to form
pounds per day could be screened using current tech-hydrogen bonds with each purine site ligand. For exam-
nologies. SPR binding assays can be used to screen forple, uric acid recruits a water molecule (W2002) that is
new allosteric inhibitors targeted to a particular effectorabsent in the caffeine complex but present in the ribofla-
locus by blocking all other binding sites with appropriatevin complex where it forms a long hydrogen bond (3.4 A˚)
compounds.to riboflavin. This water is not observed in the caffeine
structure, as it is displaced by caffeine’s 7-methyl group.
Uric acid also forms a hydrogen bond to W2003, which
Significanceis not present in either of the other two complexes due
to the lack of a nearby hydrogen-bonding partner in
Type 2 diabetes is a growing healthcare problem in theeither caffeine or riboflavin. Caffeine also recruits a water
United States and throughout the world. The metabolicmolecule (W2004) that is not found in the other two
basis of the disease is complicated, involving bothstructures either because of steric overlap (riboflavin)
resistance to insulin action and defects in pancreaticor because there is no hydrogen-bonding partner for it
insulin secretion, leading to devastating long-termat that location (uric acid).
complications such as atherosclerosis, blindness, and
liver and kidney disease. Extended studies have shownConclusions
that when blood glucose levels are maintained withinWe have studied the binding of purine and flavin com-
pounds to the human liver isozyme of glycogen phos- the normal range, the extent and progression of com-
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HLGPa (Protein Data Bank ID code 1EXV) as a starting model. Re-plications can be significantly reduced. However, such
finement was carried out using iterative cycles of manual refittingcontrol is difficult to achieve using current therapies,
in O [25] followed by refinement in CNS [26]. Ligand structures wereand more effective treatments are needed. Human
generated and minimized using SYBYL (Tripos, Inc.) or PRODRG
liver glycogen phosphorylase catalyzes the break- [27] and CNS. The crystal, data collection, and refinement statistics
down of liver glycogen stores to supply glucose for the are given in Table 1.
blood; inhibition of glycogen phosphorylase results in
lowered blood glucose in a mouse model of diabetes Biosensor Assays
Surface plasmon resonance experiments were performed on a BIA-and thus presents a potential drug design target for
CORE 2000 instrument equipped with research grade CM5 sensordiabetes.
chips (BIAcore AB, Uppsala, Sweden). All HLGP surfaces were pre-Typically, drug development efforts have focused
pared at 35C by an amine-coupling method [28] using reagents
on the catalytic sites of enzymes, but here we consider available from BIAcore AB (N-ethyl-N-dimethylaminopropyl-car-
the possibility of identifying allosteric inhibitors. HLGP bodiimide [EDC], N-hydroxysuccinimide [NHS], and 1 M ethanol-
amine-HCl at pH 8.5). During the immobilization, the flow rate of theis regulated by multiple interacting allosteric sites,
running buffer (50 mM HEPES [pH 7.2], 100 mM KCl, 2.5 mM EGTA,each of which may be considered a potential drug
2.5 mM MgCl2, 1% dimethylsulfoxide [DMSO], 0.5 mM DTT) was 15binding locus. We used surface plasmon resonance
L/min. Flow cells were activated for 6 min with a solution containingmethods to determine the affinities of a series of com-
50 mM NHS and 0.2 mM EDC. HLGPa and HLGPb were diluted to
pounds that bind to the purine inhibitor site. Notably, 0.1 mg/mL in 10 mM sodium phosphate (pH 5.0) and injected for
the binding affinities did not track rationally with the 15 min. The remaining reactive groups were blocked with a 7 min
injection of 1 M ethanolamine-HCl at pH 8.5. Typical immobilizationchemical structures of the inhibitors. The crystal struc-
levels of the HLGP proteins were between 20,000 and 30,000 RU.tures of three representative inhibitors complexed
A nonderivatized flow cell served as a reference surface.with the enzyme revealed the reasons for this: (1) the
All small molecule binding data were collected at 20C at a flowbinding affinities are in part determined by ligand-spe-
rate of 100 L/min in a solution of running buffer (50 mM HEPES
cific water-mediated hydrogen bonds, (2) the ligands [pH 7.2], 100 mM KCl, 2.5 mM EGTA, 2.5 mM MgCl2, 1% DMSO,
bind in different orientations within the pocket, and (3) 0.5 mM DTT) for both reference and reaction surfaces. Caffeine was
dissolved directly in the running buffer at a stock concentration ofside chains within the binding site are repositioned
0.5 mM. For SPR analysis, 2-fold serial dilutions of stock caffeinedepending on the inhibitor bound. The combined bind-
solution were made in running buffer across the concentration seriesing and crystallographic data provide a basis for the
from 500 to 1.84 M. Each concentration of caffeine was dispenseddesign of new allosteric inhibitors targeting this site.
into three separate tubes and randomized in the sample racks.
Samples were injected for 24 s using the KINJECT command fol-
Experimental Procedures lowed by an injection of running buffer for 30 s. The injection flow cell
was washed using the EXTRACLEAN command after each sample
Expression, Purification, and Crystallization injection. An injection of running buffer (a “blank”) was made after
Phosphorylated human liver glycogen phosphorylase (HLGPa ) was every fifth sample injection for the purpose of “double referencing”
expressed in SF9 insect cells, purified, and assayed as described [29]. Five buffer solutions containing varying concentrations of
[9]. The unphosphorylated form (HLGPb ) was prepared from E. coli DMSO (0.95%–1.1%) were injected to construct a calibration plot
cells, purified, and assayed as described [9]. Both the HLGPa and [30], which was used to correct for excluded volume differences
HLGPb preparations concluded with a Mono Q column chromatog- between the reaction and reference surfaces. The entire caffeine
raphy step that efficiently separates the phosphorylated and un- binding experiment was repeated five times using new sensor chips
phosphorylated enzymes. In addition, activity assays were used to and different preparations of HLGPa and HLGPb proteins as well
determine the relative amounts of HLGPa and HLGPb in each sam- as new caffeine stocks. Data for caffeine with 50 mM glucose added
ple. In each case, the samples are estimated to have less than 10% to the running buffer and samples were measured in the same way.
of the contaminating phosphorylation state. A set of ligands (adenosine, allantoin, allopurinol, 6-biopterin, caf-
In preparation for crystallization, HLGPa was concentrated to feine, flavin adenine dinucleotide, flavin mononucleotide, folic acid,
25–30 mg/ml in 20 mM NaBES (pH 6.8), 1 mM EDTA, and 0.5 mM hypoxanthine, inosine, 1-methylxanthine, 3-methylxanthine, 7-methyl-
dithiothreitol (DTT). After concentration, the allosteric effectors CP- xanthine, riboflavin, theophylline, uric acid, xanthine, and xanthop-
403,700, N-acetyl--D-glucopyranosylamine, and either caffeine, terin) was tested for binding to the HLGP surfaces using the proce-
uric acid, or riboflavin were added at concentrations of 0.1 mM, 0.1 dure described above for caffeine, with the following alterations.
mM, and 5 mM, respectively. Hanging drops were made with equal Due to solubility concerns, each ligand was initially dissolved in
volumes of the protein complex and the reservoir solution (0.1 M pure DMSO; the DMSO stock solutions of each compound were then
NaMES [pH 6.0] and 25%–35% methylpentanediol [MPD]), and crys- diluted in DMSO-free running buffer, giving a final DMSO content of
tals were grown at 17C. 1% that matched the running buffer. Further dilutions were made
The unphosphorylated HLGPb was concentrated to 15 mg/ml in serially in running buffer across a ligand concentration range from
20 mM NaBES (pH 6.8), 1 mM EDTA, and 0.5 mM DTT. The allosteric 1 to 0.001 mM. The entire screen was repeated twice using a newly
effectors caffeine, CP-403,700, and N-acetyl--D-glucopyranosy- prepared protein surface each time.
lamine were added at concentrations of 0.1 mM, 0.1 mM, and 5
mM, respectively. Hanging drops were made with equal volumes of Biosensor Data Analysis
protein and reservoir solution (0.1 M NaMES [pH 6.0] and 36%–40% The raw response data were zeroed on both the response and time
MPD), and crystals were grown at 17C. axes prior to the start of the injection. To correct for bulk refractive
index changes, responses from a reference surface without protein
were subtracted from the reaction surface data. In a second refer-Data Collection and Structure Solution
Prior to data collection, the HLGPa and HLGPb cocrystals were encing step, the average of the responses from five buffer injections
was used to correct for any systematic differences between flowflash frozen in liquid nitrogen directly from the drop. The data for
the HLGPa complexes were measured using a Brandeis B4 CCD cells [29]. To extract equilibrium dissociation constants, we plotted
binding responses at equilibrium against ligand concentration anddetector [23] at beamline X12C, Brookhaven National Light Source;
the data for the HLGPb complex were obtained at beamline 5.0.2 of fit the data to a 1:1 interaction site model. Before fitting the data to
the model, the response data from the screen were first normalizedthe Advanced Light Source, Berkeley, CA. The data were processed
using Denzo and Scalepack [24]. The structures were solved by by dividing by the molecular mass of each compound. In the case
of the purine site screen, the capacity of the chip was not saturatedmolecular replacement using the published structure of the inactive
Chemistry & Biology
924
for some weak affinity compounds (although binding reached equi- (1978). The regulation of glycogen phosphorylase a by nucleo-
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